为您找到"
glp-1ra
"相关结果约100,000,000个
GLP-1 agonists are injectable drugs that mimic a hormone that lowers blood sugar and promotes weight loss. Learn about the types, benefits, risks and side effects of GLP-1 agonists for Type 2 diabetes and obesity.
GLP-1 receptor agonists are drugs that mimic the hormone GLP-1 and reduce blood sugar and weight by activating the GLP-1 receptor. They are used for type 2 diabetes, obesity, and other conditions, and have various benefits and risks.
Head-to-head clinical studies. The GLP-1 RA agents have all been evaluated extensively in phase III clinical programs. Through a review of phase III clinical trials for exenatide twice daily, lixisenatide, liraglutide, exenatide once weekly, dulaglutide, semaglutide, and oral semaglutide, we identified 14 head-to-head trials that evaluated the safety and efficacy of GLP-1 RA active comparators ...
The first GLP-1 receptor agonist (GLP-1RA) outcome trial, with liraglutide, was reported in 2016 (ref. 154), and the first GLP-1 co-agonist, tirzepatide, was approved in 2022 for T2D (ref. 155 ...
While technically considered a "dual GIP/GLP-1 RA", it has many of the same effects as the other GLP-1 RAs. Effectiveness. GLP-1 RAs offer many health benefits including improved blood glucose (sugar) and A1C levels and weight loss. Some GLP-1 RAs have also been shown in clinical trials to lower the risk of heart attack or stroke.
Study design. This retrospective, observational cohort study used data from Komodo's Healthcare Map to compare outcomes between people using both newer generation GLP-1RA and SGLT2i and those using SGLT2i without GLP-1RA (See Supplementary Fig. 1, Supplementary Materials).This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines [].
Learn how GLP-1 receptor agonists, a type of non-insulin injectable medication, can help lower blood sugar and aid weight loss for people with type 2 diabetes.
Among the 396 963 eligible patients with T2D, 33 858 were included in the GLP-1RA vs other glucose-lowering drug (GLD) cohort, 34 185 in the SGLT2i vs other GLD cohort, and 24 117 in the GLP-1RA vs SGLT2i cohort. Exposures: Initiation of treatment with a GLP-1RA, SGLT2i, or other second-line GLD. Main ...
Glucagon-like peptide-1 receptor agonists (GLP-1RA, GLP-1DAs, incretin mimetics, or GLP-1 analogs) are a class of medications utilized in treating type 2 diabetes and obesity. Clinical trials show the superiority of GLP-1RA to other antihyperglycemic drugs in improving glycemic efficacy, reducing weight and blood pressure, and having a cardioprotective effect, all without the risk of ...
Glucagon-like peptide-1 receptor agonists, more commonly referred to as GLP-1s, have undoubtedly garnered much fanfare the past five years. This class of medications is prescribed for many indications including diabetes, weight loss, and to reduce the risk of heart attack and stroke in adults with heart disease. The first GLP-1, Byetta (exenatide), was approved by the Food and Drug ...